Clinical Outcomes After Week-12 Response-Guided Secukinumab Discontinuation in Psoriasis: A Prospective Real-World Cohort Study

BioDrugs · Published 2026-08-03 · DOI 10.1007/s40259-026-00801-0

Authors (12)

Xin Ma, Yue Jiang, Dongmei Liu, Quanruo Xu, Fanlingzi Shen, Zhen Duan, Xiangjin Gao, Xiuqi Zhang, Ruiqi Cai, Rui Zhang, Bin Li, Ruiping Wang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Ma, X., Jiang, Y., Liu, D., et al. (2026). Clinical Outcomes After Week-12 Response-Guided Secukinumab Discontinuation in Psoriasis: A Prospective Real-World Cohort Study. BioDrugs. https://doi.org/10.1007/s40259-026-00801-0

Related articles

• Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms · Drugs in Context · 2025 · Cites or is cited by this article
• mRNA Vaccines for Influenza: Hope for a Universal Vaccine? · BioDrugs · 2026 · Same journal
• Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability · BioDrugs · 2025 · Same journal
• Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential · BioDrugs · 2025 · Same journal
• Hemp-Derived Extracellular Vesicles: A Novel Frontier in Nanomedicine and Therapeutics · BioDrugs · 2026 · Same journal
• Interleukin-23 Inhibitors in Inflammatory Bowel Disease · BioDrugs · 2026 · Same journal
• Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline · BioDrugs · 2025 · Same journal
• Site-Specific Genomic Markers Associated with Outcomes of PD-1 Blockade in Gastric and Esophagogastric Junction Cancer: Analysis of Japan’s C-CAT Registry · BioDrugs · 2026 · Same journal
• Individual Prescribing Incentives for Biosimilars in Selected European Countries and the USA: a Scoping Literature Review · BioDrugs · 2025 · Same journal
• Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study · BioDrugs · 2025 · Same journal